Biomarker Discovery & Advanced Technologies (BioDAT) Laboratory, Scientific Institute for Research, Hospitalization and Health Care (IRCCS) San Raffaele Pisana, Via della Pisana 235, 00163, Rome, Italy.
Anticancer Res. 2014 Mar;34(3):1153-61.
Signaling pathways triggered by increased thrombin or plasminogen activator inhibitor-1 (PAI-1) expression drastically alter the tumor microenvironment, contributing to an adverse outcome. This study aimed to evaluate the prognostic value of coagulation/fibrinolytic activities in breast cancer (BC).
Coagulation/fibrinolytic activities were investigated in 187 patients with breast cancer, with respect to possible associations with clinicopathological features and survival outcomes.
Levels of plasma PAI-1 (p<0.001), D-dimer (p=0.037) and activated protein C-dependent thrombin generation (p=0.003) were higher in women with breast cancer compared to 187 healthy women. PAI-1 directly correlated with D-dimer levels (p=0.009) and Ki67 expression (p=0.027), which were both predictors of elevated PAI-1 levels at multivariate regression analysis. Cox analysis demonstrated that an elevated plasma PAI-1 level had a negative prognostic impact in terms of relapse-free (hazard ratio=2.5, p=0.021) and overall survival (hazard ratio=2.7, p=0.002).
Determination of plasma PAI-1 levels might provide important prognostic information in risk stratification and survival outcomes for patients with breast cancer.
由凝血酶或纤溶酶原激活物抑制剂-1（PAI-1）表达增加引发的信号通路极大地改变了肿瘤微环境，导致不良结局。本研究旨在评估凝血/纤溶活性在乳腺癌（BC）中的预后价值。
对 187 例乳腺癌患者的凝血/纤溶活性进行了研究，以评估其与临床病理特征和生存结果的可能相关性。
与 187 名健康女性相比，患有乳腺癌的女性的血浆 PAI-1（p<0.001）、D-二聚体（p=0.037）和活化蛋白 C 依赖性凝血酶生成（p=0.003）水平更高。PAI-1 与 D-二聚体水平（p=0.009）和 Ki67 表达（p=0.027）直接相关，这两者在多变量回归分析中均是 PAI-1 水平升高的预测因子。Cox 分析表明，血浆 PAI-1 水平升高对无复发生存（危险比=2.5，p=0.021）和总生存（危险比=2.7，p=0.002）具有负向预后影响。
确定血浆 PAI-1 水平可能为乳腺癌患者的风险分层和生存结果提供重要的预后信息。
